Timolol for the Treatment of Acne and Rosacea
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02774590|
Recruitment Status : Recruiting
First Posted : May 17, 2016
Last Update Posted : January 15, 2019
This research is being done to determine the safety and tolerability of timolol in the treatment of acne and rosacea. The investigators will also look for specific biomolecular changes in acne or rosacea skin when it is exposed to timolol.
Timolol is approved by the Food and Drug Administration (FDA) for the treatment of glaucoma. In dermatology, it has been used as a treatment to decrease the size of vascular (blood vessel) malformations in infant skin. Timolol is not approved for use in acne or rosacea and its use in this study is investigational.
Many people with rosacea have telangiectasias which are small, red dilated blood vessels on the skin. They also suffer from flushing and acne-like lesions. Better treatments than those currently available are desired.
Acne vulgaris, or acne, is another chronic inflammatory and very common skin disease that affects about 8 out of 10 young adults and adolescents. Signs of acne include papules and blackheads that are often called primary lesions because they represent an active form of the disease. There are also secondary lesions that can form later; they are known as acne scars
|Condition or disease||Intervention/treatment||Phase|
|Acne Vulgaris Rosacea||Drug: Timolol||Phase 1|
Rosacea affects roughly 16 million Americans who desire better treatments than those currently available. Acne vulgaris, another chronic inflammatory skin disorder, mainly affects teenagers but also affects 20-40% of adults. Investigating potential new treatments will not only satisfy a clinical need, but also offers the opportunity to learn about the pathogenesis of the disease and skin biology. The purpose of this study is to investigate the possible role of timolol as a therapy for the erythema and papules associated with acne and rosacea. It has been shown that timolol is beneficial and safe to treat infantile hemangiomas. The investigators hypothesize that it may also be safe and effective in the treatment of acne and rosacea.
In a single experiment where the test case was the PI (a practicing physician), the investigators treated his rosacea with timolol for this off-label indication and have noticed an improvement in flushing and an unexpected improvement in acneiform eruptions associated with the rosacea. After 30 days, less flushing and acneiform lesions were noted on the treated right side compared to the left side . Similarly, at 60 days after treatment, as visualized by infrared imaging, significantly less inflammation and flushing was noted on the treated right side even outside of episodes of flushing. The improvement was durable, such that after a 60 day washout, improvements were still noted. In summary, during testing of the PI as a case subject, timolol appeared effective, safe, and with some disease-remissive effects.
Our aim is to conduct a 16 week split-face pilot study with up to 30 patients who have a diagnosis of either inflammatory acne or rosacea to assess whether timolol maleate effectively reduces erythema, flushing, telangiectasias, and/or papules. The investigators also propose to biopsy a subset of our study patients to examine the biological activity in the skin before and after treatment. The investigators are particularly interested in studying epigenetic DNA methylation abnormalities in these conditions at baseline to compare to normal subjects and as a result of therapy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Timolol for the Treatment of Acne and Rosacea|
|Study Start Date :||March 2016|
|Estimated Primary Completion Date :||March 2020|
|Estimated Study Completion Date :||March 2022|
Experimental: Timolol to split face for 8 weeks
All 24 subjects will receive study drug and everyone will be randomized to which side of the face is treated with study drug first (right half-face versus left half-face). After 8 weeks of split-face treatment every night before bed, the subjects will be instructed to start treating both sides for another 8 weeks. Up to 30 subjects may be enrolled to ensure a target sample size of 24 (12 acne cases, 12 rosacea cases). This is an exploratory study. No part of this protocol will be considered routine care.
Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
- Safety and tolerability of timolol for acne and rosacea as assessed by subject report [ Time Frame: 8 weeks ]To determine the safety and tolerability of Timolol in the treatment of acne and rosacea
- Safety and tolerability of timolol for acne and rosacea as assessed by physician assessment [ Time Frame: 8 weeks ]To determine the safety and tolerability of Timolol in the treatment of acne and rosacea
- Decrease of rosacea activity as assessed through visual assessments (photographs, chronometer, patient report and physician examination) [ Time Frame: 8 weeks ]In rosacea, to measure decreases of disease activity-- redness.
- Decrease of acne activity: papules [ Time Frame: 8 weeks ]In acne, to measure decreases of disease activity: papules
- Test if the DNA methylation patterns are corrected following clinical improvement as assessed by microarray [ Time Frame: 8 weeks ]In both conditions, test if the DNA methylation patterns specific to each is corrected following clinical improvement after timolol treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02774590
|Contact: Bao Chau Lyemail@example.com|
|United States, Maryland|
|Johns Hopkins Dermatology Department||Recruiting|
|Baltimore, Maryland, United States, 21209|
|Contact: Sabrina Alessi 410-502-7546 firstname.lastname@example.org|
|Contact: Jasmine Mensah 410-502-7546 email@example.com|
|Principal Investigator:||Luis A Garza, MD, PhD||Johns Hopkins Dermatology|